Phase 2 N=22 Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures
Long Bone Delayed-Union Fracture
Primary: Percentage of Responders at 6 Months (Efficacy of ALLOB) — 100 percent of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Thyroid Cancer
Primary: Median Progression Free Survival — 12.5 months
Phase 2 N=114 A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
Prostate Cancer
Primary: Change in Sexual Activity Score of Psychosexual Daily Questionnaire (PDQ-4) — 0.04; 0.45; -0.02; 0.12 units on a scale
Phase 2 N=43 BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
Breast Cancer
Primary: Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer — 350 mg
Phase 2 N=27 MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
Pancreatic Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants
Phase 2 N=47 A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
NAFLD · NASH
Primary: Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16 — -0.57; -0.17 "mmol/L" — p=0.029
Phase 2 N=541 Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine
Respiratory Disorders
Primary: Anti-Protein D (PD), Anti-Protein E (PE), Anti-type IV Pili Subunit (PilA) and Anti-ubiquitous Surface Protein A2 of Moraxella Catarrhalis (UspA2) Adjusted Geometric…
Phase 2 N=31 Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum
Hyperemesis Gravidarum
Primary: Baseline Adjusted Mean Daily Motherisk-PUQE Total Scores (Pregnancy-unique Quantification of Emesis and Nausea Scale) for Days 5-7 — 6.35; 13.22 units on a scale — p=0.01
Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
Phase 2 N=34 A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Glioblastoma
Primary: Dose-limiting Toxicities (DLTs) — 0; 0 Participants
Phase 2 N=64 Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia · Advanced Myelodysplastic Syndromes
Primary: To Reduce the Early Transplant-related Mortality.
Phase 2 N=21 Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)
Palmoplantar Pustulosis
Primary: Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at Week 20 Compared With Baseline — 16.50; 15.85; 16.50; 7.65 PPPASI Score — p=< 0.0001
Phase 2 N=20 Combination Facial Aesthetic Treatment in Millennials
Dermatological Non-Disease
Primary: FACE-Q Satisfaction With Facial Appearance Overall Scale — 42.35; 59.42 score on a scale
Phase 2 N=65 Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants
Phase 2 N=10 A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
Non-Alcoholic Steatohepatitis (NASH) · Type2 Diabetes Mellitus
Primary: Change in MRI-Proton Density Fat Fraction (MRI-PDFF) — 21.3; 14.4; -6.9 percentage fat in the liver — p=0.03125